COVID-19 Biorepository and Comprehensive Database
The COVID-19 biorepository and comprehensive database have been created to accelerate a wide variety of research efforts including characterizing the basic pathophysiology of the disease, its clinical outcomes as well as the development of diagnostic tests, vaccines and treatments. This resource has been developed in collaboration with the Massachusetts Consortium on Pathogen Readiness (MassCPR) – a multi-institutional research collaboration aiming to rapidly respond to COVID-19 and future health crises.
We adhere to all federal, state and local regulations regarding the use of bio-samples and de-identified data for human subject’s research.
The COVID-19 biorepository is a centralized resource that collects, process, stores and disseminates biological specimens and accompanying de-identified health information to qualified Tufts Medical Center, Tufts University and MassCPR investigators for use in a wide range of biomedical studies. The COVID-19 Biorepository is led by the Division of Geographic Medicine and Infectious Diseases in collaboration with the Department of Pathology and Laboratory Medicine. The biorepository functions under standard operating procedures and quality control measures for specimen collection and maintenance.
Funding for the COVID-19 Biorepository has been provided by the Tupper Research Fund and the Massachusetts Consortium on Pathogen Readiness (MassCPR).
Comprehensive COVID-19 Database
The comprehensive COVID-19 database captures de-identified clinical and epidemiological data from all people tested for COVID-19 at Tufts Medical Center and includes information from both those with and without infection. The COVID-19 Database is led by the Division of Geographic Medicine and Infectious Diseases with support from the Tufts Clinical and Translational Science Institute (CTSI).